glp-1 receptor agonist with dpp-4 inhibitor combination not recommended do combine inhibitors agonists guidance Why are DPP-4 ( Comparative effectiveness of SGLT2 inhibitors,

linagliptin is an exception, as it is primarily excreted via the bile and does not require renal dose adjustment

DPP4 inhibitors primarily target the postprandial plasma glucose (PPG), whereas, GLP1 receptor agonists target fasting plasma glucose (FPG) as well as PPG

75 Nonetheless, a subset of patients with coexisting obesity and hypertension may still derive benefit from modest BP reductions achieved with GLP-1 RAs

Your healthcare provider will guide you on the correct self-injection technique and discuss proper storage of the medication

Our patients are treated by nutritionists, mental health teams, culinary medicine in our teaching kitchen, bariatric surgeons, bariatric gastroenterology, sleep physicians, exercise physiologists, and obesity medicine specialists

Juan Francisco Merino-Torres: provided expert clinical opinion and critical revision of the manuscript for important intellectual content